SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Regulatory & Safety

Read more breaking news

 

 
News in brief

FDA approves Cervarix; also Gardasil for men

20-Oct-2009

The US Food and Drug Administration (FDA) has approved Cervarix for vaccination against HPV and also granted a new indication to its rival Gardasil, which is now permitted for use in men.

GlaxoSmithKline’s Cervarix [human papillomavirus (HPV) bivalent (types 16 and 18) vaccine, recombinant] is now approved for use on women aged 10 to 25. Cervarix is designed to prevent cervical cancers associated with oncogenic HPV types 16 and 18.

 

On the same day Merck stated that Gardasil [human papillomavirus quadrivalent (Types 6, 11, 16, and 18) vaccine, recombinant] has been approved for preventing genital warts in men aged nine to 26.

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products